Want to join the conversation?
Pharmaceutical company $MYL said that in Dec. 2015 it submitted its ANDA for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder to the US FDA. This product is the generic version of Advair Diskus indicated for treatment of asthma and reducing aggravation in patients with chronic obstructive pulmonary disease.
$AAL is getting stronger into Dec. after a strong Nov..!! I’m feeling confident about their 4Q revenue forecast for a margin rise.
$KO’s CEO Muhtar Kent to step down next year. COO James Quincey will take the helm in what is already a smooth sailing scenario. And as always, shares reflect by growing 2% after the market opened.